NEW YORK – The UK's National Institute for Health and Care Excellence on Tuesday recommended Bristol Myers Squibb's immunotherapy combination Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

The approval was supported by data from the CHECKMATE-8HW trial. The US Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as first-line ...

OS rates were not available at the time of the analysis. Patients receiving combination nivolumab and ipilimumab received 240 mg nivolumab every 3 weeks plus 1 mg/kg ipilimumab every 3 weeks for ...

Participants received 1 of 3 regimens: Nivolumab 240 mg every 3 weeks plus ipilimumab 1 mg/kg every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks Nivolumab 240 mg every 2 weeks for 6 ...

If you are taking magnesium supplements, you should limit your daily intake to 350 mg or less. Taking amounts of 5,000 mg per day can result in magnesium toxicity. This might happen by taking a very ...

No significant lowering effect for blood pressure with magnesium supplement use in people with controlled hypertension and healthy blood pressure numbers Oral magnesium at 240 mg per day safely ...